Skip to main content
OpenTrials
Completed

NCT Number: NCT01411189

Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy

Patients who require therapeutic upper gastrointestinal endoscopy, such as polypectomy, endoscopic hemostasis, percutaneous endoscopic gastrostomy (PEG), endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), will receive an intragastric spraying of NPO-11. The efficacy of NPO-11 as an anti-peristaltic agent for the endoscopic therapeutic procedures will be evaluated based on the proportion of patients with suppressed gastric peristalsis during the procedures. The degree of gastric peristalsis is assessed by an independent committee.

The safety of NPO-11 will be evaluated based on adverse events and adverse drug reactions (ADRs) observed between administration and seven days after administration.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gastric Cancer Colon Nos Polypectomy Tubular Adenoma Digestive System Diseases Digestive System Neoplasms Gastric Adenoma Gastrointestinal Diseases Gastrointestinal Neoplasms Neoplasms Neoplasms by Site Stomach Diseases Stomach Neoplasms

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Nihon Pharmaceutical Co., Ltd

Tokyo, 101-0031, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inpatients or outpatients of either sex who require therapeutic upper gastrointestinal endoscopy and meet criteria (1), (4), (6) and one from (2), (3) or (5) in the study. Patients have to provide written informed consent for voluntary participation in the study. The criteria (2) to (4) will be confirmed by the endoscopic observation just before starting the intended treatment.

  • Patients who require therapeutic upper gastrointestinal endoscopy (polypectomy, endoscopic hemostasis, PEG, EMR and ESD)
  • Patients with a differentiated-type intramucosal gastric cancer located in the upper or middle third of the stomach (≤2 cm in size, no ulcer finding, EMR or ESD)
  • Patients with a gastric adenoma (≤2 cm in size, no ulcer finding, EMR or ESD)
  • Patients with an a single intended lesion for the treatment
  • Patients without experience of PEG tube placement in case of PEG tube placement
  • Patients who are older than 20 years at the time of consent

Exclusion criteria

Patients who meet any of the following criteria will be excluded from the study beforehand. The criteria (3) and (4) will be confirmed by the endoscopic observation just before starting the intended treatment.

  • Patients with a history of surgery to the upper gastrointestinal tract
  • Patients who require emergency endoscopy
  • Patients with severe gastric stenosis or deformation which makes observation of gastric peristalsis difficult
  • Patients who require emergency endoscopic treatment except for the intended lesion
  • Patients with an ongoing cancer treatment (chemotherapy or radiotherapy)
  • Patients with pacemaker
  • Patients with known bleeding tendency or Patients with difficulty of antithrombogenic agents withdrawal
  • Patients with a history of shock or hypersensitivity to l-menthol or peppermint oil
  • Pregnant or lactating women, women of childbearing potential, or women who plan to become pregnant during the study
  • Patients who have received other investigational drugs within four months before consent or who are participating in other clinical studies
  • Patients otherwise ineligible for participation in the study in the investigator's opinion

Treatment and study plan

Menthol

Drug

20 mL NPO-11 in prefilled syringe

Primary outcomes

  1. The proportion of patients had no or mild peristalsis during the therapeutic procedures

    Time frame: 60 minutes

    No or mild gastric peristalsis is defined as when patients have no or suppressed gastric peristalsis during the therapeutic procedure (for 45 s). The degree of gastric peristalsis in the time periods is assessed by an independent committee.

Secondary outcomes

  1. Duration of peristalsis-suppressing effect

    Time frame: 60 minutes

  2. Difficulty level of the therapeutic procedure

    Time frame: 60 minutes

  3. Adverse events and adverse drug reactions

    Time frame: 7 days

Sponsors and collaborators

Lead sponsor

Nihon Pharmaceutical Co., Ltd

Industry

Registry information

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Aug 8, 2011
Registry last updated
Jun 29, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.